Alzheimer's disease
- PMID: 21371747
- DOI: 10.1016/S0140-6736(10)61349-9
Alzheimer's disease
Abstract
An estimated 24 million people worldwide have dementia, the majority of whom are thought to have Alzheimer's disease. Thus, Alzheimer's disease represents a major public health concern and has been identified as a research priority. Although there are licensed treatments that can alleviate symptoms of Alzheimer's disease, there is a pressing need to improve our understanding of pathogenesis to enable development of disease-modifying treatments. Methods for improving diagnosis are also moving forward, but a better consensus is needed for development of a panel of biological and neuroimaging biomarkers that support clinical diagnosis. There is now strong evidence of potential risk and protective factors for Alzheimer's disease, dementia, and cognitive decline, but further work is needed to understand these better and to establish whether interventions can substantially lower these risks. In this Seminar, we provide an overview of recent evidence regarding the epidemiology, pathogenesis, diagnosis, and treatment of Alzheimer's disease, and discuss potential ways to reduce the risk of developing the disease.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Protein aggregation in Alzheimer's disease: Aβ and τ and their potential roles in the pathogenesis of AD.Acta Neuropathol. 2015 Feb;129(2):163-5. doi: 10.1007/s00401-015-1387-2. Acta Neuropathol. 2015. PMID: 25600324 No abstract available.
-
Beyond diagnosis: what biomarkers are teaching us about the "bio"logy of Alzheimer disease.Ann Neurol. 2010 Mar;67(3):283-5. doi: 10.1002/ana.22020. Ann Neurol. 2010. PMID: 20373338 No abstract available.
-
Alzheimer's disease.Lancet. 2016 Jul 30;388(10043):505-17. doi: 10.1016/S0140-6736(15)01124-1. Epub 2016 Feb 24. Lancet. 2016. PMID: 26921134 Review.
-
Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis.Expert Rev Neurother. 2010 May;10(5):683-91. doi: 10.1586/ern.10.27. Expert Rev Neurother. 2010. PMID: 20420489 Free PMC article. Review.
-
Imaging as a strategy for premortem diagnosis and staging of tauopathies.Curr Alzheimer Res. 2010 May;7(3):230-4. doi: 10.2174/156720510791050894. Curr Alzheimer Res. 2010. PMID: 20088805 Review.
Cited by
-
Molecular landscape of the overlap between Alzheimer's disease and somatic insulin-related diseases.Alzheimers Res Ther. 2024 Oct 28;16(1):239. doi: 10.1186/s13195-024-01609-2. Alzheimers Res Ther. 2024. PMID: 39465382 Free PMC article.
-
Ouabain Ameliorates Alzheimer's Disease-Associated Neuropathology and Cognitive Impairment in FAD4T Mice.Nutrients. 2024 Oct 20;16(20):3558. doi: 10.3390/nu16203558. Nutrients. 2024. PMID: 39458551 Free PMC article.
-
Intravenous chaperone treatment of late-stage Alzheimer´s disease (AD) mouse model affects amyloid plaque load, reactive gliosis and AD-related genes.Transl Psychiatry. 2024 Oct 24;14(1):453. doi: 10.1038/s41398-024-03161-x. Transl Psychiatry. 2024. PMID: 39448576 Free PMC article.
-
Dementia Prevention Research Clinic: a longitudinal study investigating factors influencing the development of Alzheimer's disease in Aotearoa, New Zealand.J R Soc N Z. 2022 Aug 24;53(4):489-510. doi: 10.1080/03036758.2022.2098780. eCollection 2023. J R Soc N Z. 2022. PMID: 39439970 Free PMC article.
-
Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders.J Physiol Sci. 2024 Sep 23;74(1):46. doi: 10.1186/s12576-024-00933-4. J Physiol Sci. 2024. PMID: 39313800 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical

